<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626327</url>
  </required_header>
  <id_info>
    <org_study_id>V59P21</org_study_id>
    <secondary_id>BB-IND 11278</secondary_id>
    <nct_id>NCT00626327</nct_id>
  </id_info>
  <brief_title>Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers</brief_title>
  <official_title>A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy
      toddlers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With a Seroresponse to Measles, Mumps, Rubella and Varicella Following Concomitant Administration of MMRV Vaccine With MenACWY-CRM Vaccine</measure>
    <time_frame>6 weeks post vaccination</time_frame>
    <description>Percentages of subjects with seroresponses to measles, mumps, rubella and varicella after one dose of MMRV vaccine (at 12 months) when given concomitantly with MenACWY-CRM vaccine compared to when MMRV vaccine was given alone, are reported.
Seroresponse was defined as the percentage of initially seronegative subjects who show seroconversion to measles (≥255 mIU/mL), mumps (≥10 ELISA Ab units), rubella (≥10 IU/mL) and the percentage of initially seronegative subjects who show seroprotection (≥5 gp ELISA units/mL) for varicella.
Immunogenicity to measles, mumps, rubella and varicella at 6 weeks after vaccination with one dose of MMRV given concomitantly with MenACWY-CRM was considered non-inferior to immunogenicity of MMRV administered alone if the lower limit of two-sided 95% CI of the difference in the percentage of subjects with seroconversion for measles, mumps, and rubella, and seroprotection for varicella was greater than -5% (measles, mumps and rubella) and -10% (varicella).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Titers ≥1:8 Following Concomitant Administration of MenACWY-CRM Vaccine With MMRV Vaccine.</measure>
    <time_frame>6 weeks post second dose</time_frame>
    <description>Percentages of subjects with hSBA ≥1:8, against N.meningitidis serogroups A, C, W-135, and Y following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months) when concomitantly administered with MMRV vaccine (12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.
The serum bactericidal antibodies directed against N.meningitidis serogroups A, C, W-135, and Y, were measured by human complement Serum Bactericidal Assay (hSBA).
The immune response of MenACWY-CRM given concomitantly with MMRV was considered non-inferior to the immunogenicity of MenACWY-CRM administered alone if the lower limit of the two-sided 95% CI around the difference of the percentage of subjects with hSBA ≥1:8 at 6 weeks after the second dose of MenACWY-CRM given to 12-month old toddlers {P MMRV+MenACWY minus P MenACWY} was greater than -10% for each serogroup.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With hSBA ≥1:8 Following Two Doses of MenACWY-CRM Vaccine</measure>
    <time_frame>6 weeks post vaccine dose 2</time_frame>
    <description>The antibody response following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months) was considered adequate if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA ≥1:8, at 6 weeks following the second dose of MenACWY-CRM, was greater than 85% for serogroups C, W-135, or Y and greater than 65% for serogroup A.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥1:4 After Two Doses of MenACWY-CRM Vaccine</measure>
    <time_frame>6 weeks post vaccine dose 2</time_frame>
    <description>The percentages of subjects with hSBA ≥1:4 directed against N. meningitidis serogroups A, C, W-135, and Y following two doses of MenACWY-CRM vaccine (at 7-9 and 12 months of age) when given concomitantly with MMRV vaccine (at 12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers Against Serogroups A, C, W-135 and Y, Following Two Doses of MenACWY-CRM Vaccine</measure>
    <time_frame>6 weeks post vaccine dose 2</time_frame>
    <description>The geometric mean titers (GMTs) directed against N.meningitidis serogroups A, C, W-135 and Y, following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months of age), when given concomitantly with MMRV vaccine (at 12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers Against Measles, Mumps, Rubella and Varicella Following One Dose of MMRV Vaccine.</measure>
    <time_frame>6 weeks post vaccination</time_frame>
    <description>The GMTs directed against measles, mumps, rubella and varicella, following one dose of MMRV vaccine (at 12 months) when given concomitantly with MenACWY-CRM vaccine compared to when MMRV vaccine was given alone, are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Showing Seroconversion Response to Varicella Following Concomitant Administration of MMRV With MenACWY-CRM Vaccine.</measure>
    <time_frame>6 weeks post vaccination</time_frame>
    <description>The percentages of subjects showing seroconversion response to varicella after concomitant administration of MMRV vaccine (at 12 months) with MenACWY-CRM vaccine compared to when MMRV vaccine is given alone, is reported .
Seroconversion for varicella is defined as percentage of subjects who show pre-vaccination antibody titer &lt;1.25 gp ELISA units/mL to a post-vaccination antibody titer ≥1.25 gp ELISA units/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥1:4 and hSBA ≥1:8 Following One Dose of MenACWY-CRM Vaccine</measure>
    <time_frame>1 month post vaccine dose 1</time_frame>
    <description>The percentages of subjects with hSBA ≥1:4 and hSBA ≥1:8 after one dose of MenACWY-CRM vaccine (at 7-9 months), are reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers After One Dose of MenACWY-CRM Vaccine</measure>
    <time_frame>1 month post vaccine dose 1</time_frame>
    <description>The immunogenicity of one dose of MenACWY-CRM vaccine given at 7 to 9 months of age was assessed in terms of GMTs directed against N.meningitidis serogroups A, C, W-135, and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination</measure>
    <time_frame>upto 7 days after any vaccination</time_frame>
    <description>Safety and tolerability of MenACWY-CRM and MMRV vaccines when given concomitantly compared to when either MenACWY-CRM or MMRV vaccine was administered alone is reported in terms of the number of subjects with local and systemic adverse events after vaccination.
Systemic reactions including axillary temperature reported during 28 days after vaccination at 12 months of age. These included the following systemic reactions: Measles-like rash, Rubella-like rash, Varicellalike rash, injection site rash, Mumps-like symptoms and axillary temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination</measure>
    <time_frame>Day 1- Day 180 (Through out the study)</time_frame>
    <description>The safety profile of MenACWY-CRM and MMRV vaccines when given concomitantly as compared to when MenACWY-CRM or MMRV was given alone is reported in terms of number of subjects reporting unsolicited adverse events (AEs), medically significant adverse events and serious adverse events (SAEs) after vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1630</enrollment>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>MenACWY-CRM+ MMRV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MMRV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM + MMRV</intervention_name>
    <description>One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.</description>
    <arm_group_label>MenACWY-CRM+ MMRV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMRV</intervention_name>
    <description>one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age</description>
    <arm_group_label>MMRV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age</description>
    <arm_group_label>MenACWY-CRM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  who are healthy 7 to 9 months old or 12 months old (inclusive plus 14 days) and for
             whom, after the nature of the study has been explained, the parent or legal guardian
             has provided written informed consent;

          -  who have received complete primary vaccination with recommended licensed vaccines;

          -  who are available for all visits and telephone calls scheduled for the study;

        Exclusion Criteria:

          -  whose parent or legal guardian is unwilling or unable to give written informed assent
             consent

          -  who had a previous or suspected disease caused by N. meningitidis;

          -  who had previous or suspected infection with measles, mumps, rubella, varicella,
             and/or herpes zoster;

          -  who had household contact with and/or intimate exposure to an individual with
             culture-proven N. meningitidis infection within 60 days prior to enrollment;

          -  who had household contact with and/or intimate exposure to an individual with measles,
             mumps, rubella and/or varicella infection within 60 days prior to enrollment;

          -  who have previously been immunized with a meningococcal vaccine or vaccine containing
             meningococcal antigen(s)

          -  who have previously received any measles, mumps, rubella or varicella vaccine either
             alone or in any combination;

          -  who have received any investigational agents or vaccines within 90 days prior to
             enrollment or who expect to receive an investigational agent or vaccine prior to the
             completion of the study;

          -  who have any serious acute, chronic or progressive disease such as, cancer, diabetes,
             heart failure, malnutrition, epilepsy, HIV/AIDS, Guillain Barre Syndrome

          -  who have a history of anaphylaxis, serious vaccine reactions or allergy to any part of
             the vaccine,

          -  who have a known or suspected impairment/alteration of immune function, either
             congenital or acquired

          -  who have Down's syndrome or other known cytogenic disorders; bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Months</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 85 - Birmingham Pediatric Associates, 806 St. Vincent's Drive</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 86 - Southeastern Pediatrics Associate, 364 Honeysuckle Road</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 00 - Veritas Research LLC/ Stabler Clinic, 300 North College Street,</name>
      <address>
        <city>Greenville</city>
        <state>Alabama</state>
        <zip>36037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42 - Drug Research and Analysis Corporation, 1758 Parkplace, Suite 200</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 56 - Children's Investigational Research Program, LLC, 2719 SE I Street</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 94 - Central Arkansas Pediatrics, 2425 Dave Ward Dr.; Suite 601</name>
      <address>
        <city>Conway</city>
        <state>Arkansas</state>
        <zip>72034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 80 - The Children's Clinic of Jonesboro, 800 S. Church St; Suite 400; 4th Fl</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49 - Arkansas Pediatric Clinical Research, 500 S. University; Suite 200</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05 - Kaiser Permanente Pediatric Clinic 395 Hickory Blvd. 2nd Floor; Room 265</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 08 - Kaiser Permanente Pediatric Clinic 4785 N. First Street 3rd Floor</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 70 - Loma Linda University, Department of Pediatrics, 11175 Campus Street; CP A1120</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 71 - LLUHC Moreno Valley Pediatrics, 11401 Heacock Street</name>
      <address>
        <city>Moreno Valley</city>
        <state>California</state>
        <zip>92557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34 - Children's Hospital and Research Center Oakland (CHRCO), Infectious Diseases Department, 747 52nd Street</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 72 - Children's Hospital of Orange Co. 455 South Main Street</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 58 - Center for Clinical Trials, LLC 16660 Paramount Boulevard Suite 301</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 59 - Center for Clinical Trials, LLC 16415 S. Colorado Avevue Suite 308</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04 - Kaiser Permanente Pediatric Clinic, 610 Walnut Street, Room 110</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37 - Kaiser Permanente Pediatric Clinic 901 Nevin Ave. Room 1E24</name>
      <address>
        <city>Richmond</city>
        <state>California</state>
        <zip>94801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 09 - Kaiser Permanente Pediatric Clinic 1840 Sierra Gardens Vaccine Studies</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 03 - Kaiser Permanente Pediatric Clinic, Point West Medical Offices, 1650 Response Road</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48 - Pediatric Infectious Diseases Admin 2516 Stockton Blvd.; Ticon II</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10 - Kaiser Permanente Pediatric Clinic 6600 Bruceville Road Pediatric Station C</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50 - Kaiser Permanente Pediatric Clinic 3925 Old Redwood Hwy</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24 - UCLA Center for Vaccine Research 1124 W Carson St.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07 - Kaiser Permanente Pediatric Clinic 975 Sereno Drive; 1st Floor MOB Pediatric Station 1</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02 - Kaiser Permanente Pediatric Clinic, 1425 S. Main Street; MOB2, 4th Floor; Station 2</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40 - 1st Allergy and Asthma Center 3260 E. 104th Ave.; Suite C</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41 - 1st Immunology &amp; Clinical Research 3260 East 104th Avenue</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 60 - Norwich Pediatric Group, PC 92 New London Turnpike</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47 - Department of Clinical Trials 1401Lucerne Terrace; MP141</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25 - Kentucky Pediatric/ Adult Research 201 South 5th Street Suite 102</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52 - Cincinnati Children's Hosp Med Ctr Gamble Program for Clinical Studies 2865 Chancellor Drive</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 74 - University of Louisville University Child Health Specialists 230 East Broadway</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 87 - University of Louisville Children &amp; Youth Project 555 South Floyd Street</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 88 - University of Louisville Univ. of Child Health Specialist So 9702 Stonestreet Road; Suite 100</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 57 - Bluegrass Clinical Research, Inc. 5512 Bardstown Rd; Suite 2</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 84 - Springs Medical Research, PLLC 2200 East Parrish Avenue Suite 101</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 68 - Physicians to Children/ Adolescents 102 West Depot Street</name>
      <address>
        <city>Springfield</city>
        <state>Kentucky</state>
        <zip>40069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 93 - ACC Pediatric Research 1025 Highway 80 East</name>
      <address>
        <city>East Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 63 - Ochsner Clinic Foundations, 1315 Jefferson Highway</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 39 - Pediatric Associates of Fall River, 829 S. Main Street</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 96 - Southwestern Medical Clinic, PC 2002 South 11th Street</name>
      <address>
        <city>Niles</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 89 - Southwestern Medical Clinic 5515 Cleveland Ave.; Suite 1</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 73 - University of MS Medical Ctr Pediatric Clinical Research 2500 North State St; 2 East-H255</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 79 - Children's Physicians Bellevue 11507 S. 42nd Street</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 66 - Creighton University Department of Pediatrics 601 N. 30th St.; Suite 6820</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 78 - Children's Physicians Dundee 119 North 51st Street</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 77 - Montefiore Medical Center 111 East 210th Street Rosenthall Building; 4th Floor</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 76 - Winthrop University Hospital Winthrop Pediatric Associates 120 Mineola Boulevard, Suite 210</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 91 - SUNY Upstate Medical University 750 East Adams St,; Suite 5400</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28 - Duke Health Center at Roxboro Road 4020 North Roxboro Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29 - Regional Pediatrics 4022 Freedom Lake Drive</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30 - Durham Pediatrics 2609 North Duke Street Suite 100</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 82 - Austintown Pediatrics 107 Javit Court</name>
      <address>
        <city>Austintown</city>
        <state>Ohio</state>
        <zip>44515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51 - Cincinnati Children's Hosp Med Ctr Gamble Program for Clinical Studies 3333 Burnet Avenue; MLC 6014</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 62 - Dr. Senders and Assoc., Pediatrics 2054 South Green Road</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 97 - Dayton Clinical Research 1100 Salem Avenue</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35 - Caro Pediatric Center 111 Turner Road</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26 - Ohio Pediatrics 7371 Brandt Pike; Suite C</name>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27 - Ohio Pediatrics 1775 Delco Park Drive</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 90 - OK State Univ-Ctr for Health Scienc Houston Parke Physicians 635 W. 11th StreetOklahoma State University - Center for Health Sciences</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31 - Calcagno Research and Development 24850 SE Stark Street Suite 150</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32 - Drexel Hill Pediatrics 5030 State Rd.; Suite 2-900</name>
      <address>
        <city>Drexel Hill</city>
        <state>Pennsylvania</state>
        <zip>19026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13 - Children's Health Care- West 4671 West Lake Road</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15 - UPMC/ Community Medicine, Inc 90 Shenango Street</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19 - Pediatric Associates of Latrobe 210 Welson Street</name>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18 - Squirrel Hill Office 4070 Beechwood Blvd</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21 - Pediatric Alliance Greentree Div. 969 Greentree Road Suite 100</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20 - South Hill Pediatrics 4411 Stilley Road</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17 - Pediatric Alliance, Southwestern, 850 Clairton Blvd</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 83 - Pediatric Alliance, PC Arcadia Division 9000 Perry Hwy; Suite 120</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12 - Pediatric Alliance St. Clair 1580 McLaughlin Run Road</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16 - Laurel Pediatrics 140 Wayland Smith Drive</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14 - CCP - Pittsburgh Pediatrics 6000 Brooktree Road Suite 207</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 81 - Alpha Clinical Research, LLC 279 Clear Sky Court; Suite C</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11 - Focus Research Group 242 West Main</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38 - Jackson Clinic 2683 Highway 45 Bypass North</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 69 - University of North Texas Health Science Center 855 Montgomery Street</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36 - Pediatric Healthcare of Northwest Houston P.A. 13406 Medical Complex Drive Suite 200</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43 - Wee Care Pediatrics 1580 W. Antelope Drive; Suite 100</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45 - Wee Care Pediatrics 934 South Main St.; Suite 8</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44 - Wee Care Pediatrics 5991 South 3500 West; Suite 100 Rock Run Plaza</name>
      <address>
        <city>Roy</city>
        <state>Utah</state>
        <zip>84067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53 - Copperview Medical Center 3556 West 9800 South Suite 101</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 67 - Virginia Commonwealth Univ. 1001 East Marshall Street Room P008</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 55 - Children's Hosp. &amp; Regional Med Ctr 4800 Sand Point Way NE; MS 5441</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06 - Rockwood Clinic, P.S. 400 East Fifth Avenue</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46 - Rockwood Clinic North 9001 N. Country Homes Blvd</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 98 - University Physicians Internal Medicine 1600 Medical Center Drive</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 92 - Gundersen Clinic, Ltd. 1836 South Ave.; Mailstop C03-006B</name>
      <address>
        <city>LaCrosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64 - Monroe Medical Foundation Monroe Clinic 515 22nd Avenue</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>February 12, 2013</results_first_submitted>
  <results_first_submitted_qc>February 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2013</results_first_posted>
  <disposition_first_submitted>February 18, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2011</disposition_first_posted>
  <last_update_submitted>April 12, 2013</last_update_submitted>
  <last_update_submitted_qc>April 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>toddlers</keyword>
  <keyword>healthy</keyword>
  <keyword>meningitis</keyword>
  <keyword>meningococcal</keyword>
  <keyword>measles</keyword>
  <keyword>mumps</keyword>
  <keyword>rubella</keyword>
  <keyword>varicella</keyword>
  <keyword>Prevention of Meningococcal disease types ACWY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 90 centers in the USA</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY-CRM+ MMRV</title>
          <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
        </group>
        <group group_id="P2">
          <title>MMRV</title>
          <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
        </group>
        <group group_id="P3">
          <title>MenACWY-CRM</title>
          <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
                <participants group_id="P2" count="616"/>
                <participants group_id="P3" count="510"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="426"/>
                <participants group_id="P2" count="557"/>
                <participants group_id="P3" count="422"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenACWY-CRM+ MMRV</title>
          <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
        </group>
        <group group_id="B2">
          <title>MMRV</title>
          <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
        </group>
        <group group_id="B3">
          <title>MenACWY-CRM</title>
          <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="504"/>
            <count group_id="B2" value="616"/>
            <count group_id="B3" value="510"/>
            <count group_id="B4" value="1630"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="0.8"/>
                    <measurement group_id="B2" value="12.1" spread="0.3"/>
                    <measurement group_id="B3" value="8.5" spread="0.8"/>
                    <measurement group_id="B4" value="9.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="258"/>
                    <measurement group_id="B4" value="823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With a Seroresponse to Measles, Mumps, Rubella and Varicella Following Concomitant Administration of MMRV Vaccine With MenACWY-CRM Vaccine</title>
        <description>Percentages of subjects with seroresponses to measles, mumps, rubella and varicella after one dose of MMRV vaccine (at 12 months) when given concomitantly with MenACWY-CRM vaccine compared to when MMRV vaccine was given alone, are reported.
Seroresponse was defined as the percentage of initially seronegative subjects who show seroconversion to measles (≥255 mIU/mL), mumps (≥10 ELISA Ab units), rubella (≥10 IU/mL) and the percentage of initially seronegative subjects who show seroprotection (≥5 gp ELISA units/mL) for varicella.
Immunogenicity to measles, mumps, rubella and varicella at 6 weeks after vaccination with one dose of MMRV given concomitantly with MenACWY-CRM was considered non-inferior to immunogenicity of MMRV administered alone if the lower limit of two-sided 95% CI of the difference in the percentage of subjects with seroconversion for measles, mumps, and rubella, and seroprotection for varicella was greater than -5% (measles, mumps and rubella) and –10% (varicella).</description>
        <time_frame>6 weeks post vaccination</time_frame>
        <population>The analysis was performed on the MMRV per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM+ MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MMRV</title>
            <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With a Seroresponse to Measles, Mumps, Rubella and Varicella Following Concomitant Administration of MMRV Vaccine With MenACWY-CRM Vaccine</title>
          <description>Percentages of subjects with seroresponses to measles, mumps, rubella and varicella after one dose of MMRV vaccine (at 12 months) when given concomitantly with MenACWY-CRM vaccine compared to when MMRV vaccine was given alone, are reported.
Seroresponse was defined as the percentage of initially seronegative subjects who show seroconversion to measles (≥255 mIU/mL), mumps (≥10 ELISA Ab units), rubella (≥10 IU/mL) and the percentage of initially seronegative subjects who show seroprotection (≥5 gp ELISA units/mL) for varicella.
Immunogenicity to measles, mumps, rubella and varicella at 6 weeks after vaccination with one dose of MMRV given concomitantly with MenACWY-CRM was considered non-inferior to immunogenicity of MMRV administered alone if the lower limit of two-sided 95% CI of the difference in the percentage of subjects with seroconversion for measles, mumps, and rubella, and seroprotection for varicella was greater than -5% (measles, mumps and rubella) and –10% (varicella).</description>
          <population>The analysis was performed on the MMRV per-protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles (N=350,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps (N=365,499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="93" upper_limit="97"/>
                    <measurement group_id="O2" value="97" lower_limit="95" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella (N=337,459)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response to measles following one dose of MMRV administered concomitantly with MenACWY-CRM as compared to MMRV given alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM+MMRV group was considered non-inferior to that of MMRV group if the lower limit of the two-sided 95% CI of the difference in the percentage of subjects with seroconversion for measles was greater than -5%, at 6 weeks after MMRV vaccination.</non_inferiority_desc>
            <param_type>Difference % (MenACWY-CRM+MMRV-MMRV)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response to mumps following one dose of MMRV administered concomitantly with MenACWY-CRM as compared to MMRV administered alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM+MMRV group was considered non-inferior to that of MMRV group if the lower limit of the two-sided 95% CI of the difference in the percentage of subjects with seroconversion for mumps was greater than -5%, at 6 weeks after MMRV vaccination.</non_inferiority_desc>
            <param_type>Difference % (MenACWY-CRM+MMRV - MMRV )</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response to rubella following one dose of MMRV administered concomitantly with MenACWY-CRM as compared to MMRV administered alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM+MMRV group was considered non-inferior to that of MMRV group if the lower limit of the two-sided 95% CI of the difference in the percentage of subjects with seroconversion for rubella was greater than -5%, at 6 weeks after MMRV vaccination.</non_inferiority_desc>
            <param_type>Difference% (MenACWY-CRM+MMRV-MMRV)</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response to varicella following one dose of MMRV administered concomitantly with MenACWY-CRM as compared to MMRV administered alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM+MMRV group was considered non-inferior to that of MMRV group if the lower limit of the two-sided 95% CI of the difference in the percentage of subjects with seroprotection for varicella was greater than –10%, at 6 weeks after MMRV vaccination.</non_inferiority_desc>
            <param_type>Difference% (MenACWY-CRM+MMRV-MMRV)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Serum Bactericidal Titers ≥1:8 Following Concomitant Administration of MenACWY-CRM Vaccine With MMRV Vaccine.</title>
        <description>Percentages of subjects with hSBA ≥1:8, against N.meningitidis serogroups A, C, W-135, and Y following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months) when concomitantly administered with MMRV vaccine (12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.
The serum bactericidal antibodies directed against N.meningitidis serogroups A, C, W-135, and Y, were measured by human complement Serum Bactericidal Assay (hSBA).
The immune response of MenACWY-CRM given concomitantly with MMRV was considered non-inferior to the immunogenicity of MenACWY-CRM administered alone if the lower limit of the two-sided 95% CI around the difference of the percentage of subjects with hSBA ≥1:8 at 6 weeks after the second dose of MenACWY-CRM given to 12-month old toddlers {P MMRV+MenACWY minus P MenACWY} was greater than -10% for each serogroup.</description>
        <time_frame>6 weeks post second dose</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM+ MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Titers ≥1:8 Following Concomitant Administration of MenACWY-CRM Vaccine With MMRV Vaccine.</title>
          <description>Percentages of subjects with hSBA ≥1:8, against N.meningitidis serogroups A, C, W-135, and Y following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months) when concomitantly administered with MMRV vaccine (12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.
The serum bactericidal antibodies directed against N.meningitidis serogroups A, C, W-135, and Y, were measured by human complement Serum Bactericidal Assay (hSBA).
The immune response of MenACWY-CRM given concomitantly with MMRV was considered non-inferior to the immunogenicity of MenACWY-CRM administered alone if the lower limit of the two-sided 95% CI around the difference of the percentage of subjects with hSBA ≥1:8 at 6 weeks after the second dose of MenACWY-CRM given to 12-month old toddlers {P MMRV+MenACWY minus P MenACWY} was greater than -10% for each serogroup.</description>
          <population>The analysis was performed on the MenACWY per-protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="84" upper_limit="91"/>
                    <measurement group_id="O2" value="88" lower_limit="84" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroroup C (N=204,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sergroup W-135 (N=204,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=200,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="96" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response of MenACWY-CRM against serogroup A when concomitantly administered with MMRV vaccine as compared to MenACWY-CRM vaccine given alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM + MMRV group was considered non-inferior to that of MenACWY-CRM group if the lower limit of the two-sided 95% CI around the difference of the percentage of subjects with hSBA ≥1:8 at 6 weeks after the second dose of MenACWY-CRM given to 12 month old toddlers was greater than -10% for each serogroup.</non_inferiority_desc>
            <param_type>Difference% (MenACWY-CRM+MMRV-MenACWY)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response of MenACWY-CRM against serogroup C when concomitantly administered with MMRV vaccine as compared to MenACWY-CRM vaccine given alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM + MMRV group was considered non-inferior to that of MenACWY-CRM group if the lower limit of the two-sided 95% CI around the difference of the percentage of subjects with hSBA ≥1:8 at 6 weeks after the second dose of MenACWY-CRM given to 12 month old toddlers was greater than -10% for each serogroup.</non_inferiority_desc>
            <param_type>Difference% (MenACWY-CRM+MMRV-MenACWY)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response of MenACWY-CRM against serogroup W-135 when concomitantly administered with MMRV vaccine as compared to MenACWY vaccine given alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM + MMRV group was considered non-inferior to that of MenACWY-CRM group if the lower limit of the two-sided 95% CI around the difference of the percentage of subjects with hSBA ≥1:8 at 6 weeks after the second dose of MenACWY-CRM given to 12 month old toddlers was greater than -10% for each serogroup.</non_inferiority_desc>
            <param_type>Difference% (MenACWY-CRM+MMRV-MenACWY)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune response of MenACWY-CRM against serogroup Y when concomitantly administered with MMRV vaccine as compared to MenACWY-CRM vaccine given alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenACWY-CRM + MMRV group was considered non-inferior to that of MenACWY-CRM group if the lower limit of the two-sided 95% CI around the difference of the percentage of subjects with hSBA ≥1:8 at 6 weeks after the second dose of MenACWY-CRM given to 12 month old toddlers was greater than -10% for each serogroup.</non_inferiority_desc>
            <param_type>Difference% (MenACWY-CRM+MMRV-MenACWY)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With hSBA ≥1:8 Following Two Doses of MenACWY-CRM Vaccine</title>
        <description>The antibody response following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months) was considered adequate if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA ≥1:8, at 6 weeks following the second dose of MenACWY-CRM, was greater than 85% for serogroups C, W-135, or Y and greater than 65% for serogroup A.</description>
        <time_frame>6 weeks post vaccine dose 2</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA ≥1:8 Following Two Doses of MenACWY-CRM Vaccine</title>
          <description>The antibody response following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months) was considered adequate if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA ≥1:8, at 6 weeks following the second dose of MenACWY-CRM, was greater than 85% for serogroups C, W-135, or Y and greater than 65% for serogroup A.</description>
          <population>The analysis was performed on the MenACWY per-protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="84" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥1:4 After Two Doses of MenACWY-CRM Vaccine</title>
        <description>The percentages of subjects with hSBA ≥1:4 directed against N. meningitidis serogroups A, C, W-135, and Y following two doses of MenACWY-CRM vaccine (at 7-9 and 12 months of age) when given concomitantly with MMRV vaccine (at 12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.</description>
        <time_frame>6 weeks post vaccine dose 2</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM+MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA ≥1:4 After Two Doses of MenACWY-CRM Vaccine</title>
          <description>The percentages of subjects with hSBA ≥1:4 directed against N. meningitidis serogroups A, C, W-135, and Y following two doses of MenACWY-CRM vaccine (at 7-9 and 12 months of age) when given concomitantly with MMRV vaccine (at 12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.</description>
          <population>The analysis was performed on the MenACWY per-protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="86" upper_limit="92"/>
                    <measurement group_id="O2" value="91" lower_limit="87" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=204,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=204,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=200,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="95" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers Against Serogroups A, C, W-135 and Y, Following Two Doses of MenACWY-CRM Vaccine</title>
        <description>The geometric mean titers (GMTs) directed against N.meningitidis serogroups A, C, W-135 and Y, following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months of age), when given concomitantly with MMRV vaccine (at 12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.</description>
        <time_frame>6 weeks post vaccine dose 2</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM + MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Serogroups A, C, W-135 and Y, Following Two Doses of MenACWY-CRM Vaccine</title>
          <description>The geometric mean titers (GMTs) directed against N.meningitidis serogroups A, C, W-135 and Y, following two doses of MenACWY-CRM vaccine (at 7-9 months and 12 months of age), when given concomitantly with MMRV vaccine (at 12 months) compared to when MenACWY-CRM vaccine was given alone, are reported.</description>
          <population>The analysis was performed on the MenACWY per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="34" upper_limit="45"/>
                    <measurement group_id="O2" value="37" lower_limit="32" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=204,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194" lower_limit="170" upper_limit="220"/>
                    <measurement group_id="O2" value="180" lower_limit="158" upper_limit="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=204,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="113" upper_limit="155"/>
                    <measurement group_id="O2" value="119" lower_limit="101" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=200,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="81" upper_limit="116"/>
                    <measurement group_id="O2" value="88" lower_limit="73" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers Against Measles, Mumps, Rubella and Varicella Following One Dose of MMRV Vaccine.</title>
        <description>The GMTs directed against measles, mumps, rubella and varicella, following one dose of MMRV vaccine (at 12 months) when given concomitantly with MenACWY-CRM vaccine compared to when MMRV vaccine was given alone, are reported.</description>
        <time_frame>6 weeks post vaccination</time_frame>
        <population>The analysis was performed on the MMRV per-protocol population.
Only subjects with a baseline titer below the specified cut-off for that antigen were included in the immunogenicity analysis for the same antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM+ MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MMRV</title>
            <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Measles, Mumps, Rubella and Varicella Following One Dose of MMRV Vaccine.</title>
          <description>The GMTs directed against measles, mumps, rubella and varicella, following one dose of MMRV vaccine (at 12 months) when given concomitantly with MenACWY-CRM vaccine compared to when MMRV vaccine was given alone, are reported.</description>
          <population>The analysis was performed on the MMRV per-protocol population.
Only subjects with a baseline titer below the specified cut-off for that antigen were included in the immunogenicity analysis for the same antigen.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose, Measles (N=357,470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="71" upper_limit="77"/>
                    <measurement group_id="O2" value="74" lower_limit="71" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose, Measles (N=350,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4049" lower_limit="3701" upper_limit="4430"/>
                    <measurement group_id="O2" value="3632" lower_limit="3350" upper_limit="3938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Mumps (N=372,502)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose, Mumps (N=365,499)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="89" upper_limit="107"/>
                    <measurement group_id="O2" value="81" lower_limit="75" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Rubella</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose, Rubella (N=370,515)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="52" upper_limit="62"/>
                    <measurement group_id="O2" value="56" lower_limit="52" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose, Varicella (N=344,461)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.63" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.63" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose, Varicella (N=337,459)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="17" upper_limit="20"/>
                    <measurement group_id="O2" value="18" lower_limit="17" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Showing Seroconversion Response to Varicella Following Concomitant Administration of MMRV With MenACWY-CRM Vaccine.</title>
        <description>The percentages of subjects showing seroconversion response to varicella after concomitant administration of MMRV vaccine (at 12 months) with MenACWY-CRM vaccine compared to when MMRV vaccine is given alone, is reported .
Seroconversion for varicella is defined as percentage of subjects who show pre-vaccination antibody titer &lt;1.25 gp ELISA units/mL to a post-vaccination antibody titer ≥1.25 gp ELISA units/mL.</description>
        <time_frame>6 weeks post vaccination</time_frame>
        <population>The analysis was performed on the MMRV per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM +MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MMRV</title>
            <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Showing Seroconversion Response to Varicella Following Concomitant Administration of MMRV With MenACWY-CRM Vaccine.</title>
          <description>The percentages of subjects showing seroconversion response to varicella after concomitant administration of MMRV vaccine (at 12 months) with MenACWY-CRM vaccine compared to when MMRV vaccine is given alone, is reported .
Seroconversion for varicella is defined as percentage of subjects who show pre-vaccination antibody titer &lt;1.25 gp ELISA units/mL to a post-vaccination antibody titer ≥1.25 gp ELISA units/mL.</description>
          <population>The analysis was performed on the MMRV per-protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of anti-varicella response following one dose of MMRV when administered concomitantly with MenACWY vaccine as compared to MMRV administered alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MMRV+MenACWY group was considered non-inferior to that of MMRV group if the lower limit of the two-sided 95% CI of the difference in the percentages of subjects with seroconversion for varicella was greater than -10%.</non_inferiority_desc>
            <param_type>Difference% (MenACWY-CRM+MMRV- MMRV)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥1:4 and hSBA ≥1:8 Following One Dose of MenACWY-CRM Vaccine</title>
        <description>The percentages of subjects with hSBA ≥1:4 and hSBA ≥1:8 after one dose of MenACWY-CRM vaccine (at 7-9 months), are reported</description>
        <time_frame>1 month post vaccine dose 1</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA ≥1:4 and hSBA ≥1:8 Following One Dose of MenACWY-CRM Vaccine</title>
          <description>The percentages of subjects with hSBA ≥1:4 and hSBA ≥1:8 after one dose of MenACWY-CRM vaccine (at 7-9 months), are reported</description>
          <population>The analysis was performed on the MenACWY per-protocol population</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A hSBA ≥1:4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="57" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A hSBA ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="45" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=199) hSBA ≥1:4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="88" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=199) hSBA ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="83" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=199) hSBA ≥1:4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="41" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=199) hSBA ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="30" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=196) hSBA ≥1:4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="34" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=196) hSBA ≥1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="24" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers After One Dose of MenACWY-CRM Vaccine</title>
        <description>The immunogenicity of one dose of MenACWY-CRM vaccine given at 7 to 9 months of age was assessed in terms of GMTs directed against N.meningitidis serogroups A, C, W-135, and Y.</description>
        <time_frame>1 month post vaccine dose 1</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers After One Dose of MenACWY-CRM Vaccine</title>
          <description>The immunogenicity of one dose of MenACWY-CRM vaccine given at 7 to 9 months of age was assessed in terms of GMTs directed against N.meningitidis serogroups A, C, W-135, and Y.</description>
          <population>The analysis was performed on the MenACWY per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.16" lower_limit="6.96" upper_limit="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="22" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" lower_limit="4.15" upper_limit="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" lower_limit="3.36" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination</title>
        <description>Safety and tolerability of MenACWY-CRM and MMRV vaccines when given concomitantly compared to when either MenACWY-CRM or MMRV vaccine was administered alone is reported in terms of the number of subjects with local and systemic adverse events after vaccination.
Systemic reactions including axillary temperature reported during 28 days after vaccination at 12 months of age. These included the following systemic reactions: Measles-like rash, Rubella-like rash, Varicellalike rash, injection site rash, Mumps-like symptoms and axillary temperature.</description>
        <time_frame>upto 7 days after any vaccination</time_frame>
        <population>The analysis was performed on the safety set population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM+MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months</description>
          </group>
          <group group_id="O3">
            <title>MMRV</title>
            <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination</title>
          <description>Safety and tolerability of MenACWY-CRM and MMRV vaccines when given concomitantly compared to when either MenACWY-CRM or MMRV vaccine was administered alone is reported in terms of the number of subjects with local and systemic adverse events after vaccination.
Systemic reactions including axillary temperature reported during 28 days after vaccination at 12 months of age. These included the following systemic reactions: Measles-like rash, Rubella-like rash, Varicellalike rash, injection site rash, Mumps-like symptoms and axillary temperature.</description>
          <population>The analysis was performed on the safety set population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
                <count group_id="O3" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                    <measurement group_id="O2" value="298"/>
                    <measurement group_id="O3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection(Inj.) site Tenderness [MenACWY-CRM]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site Erythema [MenACWY-CRM]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj.site Induration [ MenACWY-CRM]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj.site Tenderness [MMRV (N=455,424,592)]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj.site Erythema [MMRV (N=456,425,593)]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site Induration [MMRV (456,424,593)]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371"/>
                    <measurement group_id="O2" value="372"/>
                    <measurement group_id="O3" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=500,499,595)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits (N=475,483,550)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=500,499,595)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="199"/>
                    <measurement group_id="O3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent crying (N=475,483,550)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=500,500,595)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="298"/>
                    <measurement group_id="O3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=500,499,595)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=500,499,595)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( N=499,500,596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="254"/>
                    <measurement group_id="O3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic.Antipyr.Meds (N=499,499,594)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="254"/>
                    <measurement group_id="O3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination</title>
        <description>The safety profile of MenACWY-CRM and MMRV vaccines when given concomitantly as compared to when MenACWY-CRM or MMRV was given alone is reported in terms of number of subjects reporting unsolicited adverse events (AEs), medically significant adverse events and serious adverse events (SAEs) after vaccination.</description>
        <time_frame>Day 1- Day 180 (Through out the study)</time_frame>
        <population>This analysis was done on the safety set population</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM+ MMRV</title>
            <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
          </group>
          <group group_id="O2">
            <title>MMRV</title>
            <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM</title>
            <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination</title>
          <description>The safety profile of MenACWY-CRM and MMRV vaccines when given concomitantly as compared to when MenACWY-CRM or MMRV was given alone is reported in terms of number of subjects reporting unsolicited adverse events (AEs), medically significant adverse events and serious adverse events (SAEs) after vaccination.</description>
          <population>This analysis was done on the safety set population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="597"/>
                <count group_id="O3" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="311"/>
                    <measurement group_id="O3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least probably related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All solicited adverse events (AEs) were collected upto Day 7 after each vaccination. All SAEs and unsolicited AEs were collected throughout the study (Day 1-Day 180).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MenACWY-CRM+ MMRV</title>
          <description>Subjects in this group received 2 injections of MenACWY-CRM at 7-9 and 12 months; second injection administered concomitantly with MMRV</description>
        </group>
        <group group_id="E2">
          <title>MMRV</title>
          <description>Subjects in this group received 1 injection of MMRV vaccine at 12 months of age</description>
        </group>
        <group group_id="E3">
          <title>MenACWY-CRM</title>
          <description>Subjects in this group received 2 injections of the MenACWY-CRM vaccine at 7-9 and 12 months of age followed by 1 injection of MMRV at 13.5 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="597"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Systemic inflamatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>CROUP infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Postoperative wound infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Feeding disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tethered cord syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="433" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="482" subjects_at_risk="597"/>
                <counts group_id="E3" subjects_affected="442" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="125" subjects_affected="125" subjects_at_risk="500"/>
                <counts group_id="E2" events="114" subjects_affected="114" subjects_at_risk="597"/>
                <counts group_id="E3" events="128" subjects_affected="128" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="500"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="597"/>
                <counts group_id="E3" events="60" subjects_affected="60" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="500"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="597"/>
                <counts group_id="E3" events="79" subjects_affected="79" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="219" subjects_affected="219" subjects_at_risk="500"/>
                <counts group_id="E2" events="224" subjects_affected="224" subjects_at_risk="597"/>
                <counts group_id="E3" events="230" subjects_affected="230" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="128" subjects_affected="128" subjects_at_risk="500"/>
                <counts group_id="E2" events="102" subjects_affected="102" subjects_at_risk="597"/>
                <counts group_id="E3" events="115" subjects_affected="115" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="163" subjects_affected="163" subjects_at_risk="500"/>
                <counts group_id="E2" events="180" subjects_affected="180" subjects_at_risk="597"/>
                <counts group_id="E3" events="188" subjects_affected="188" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="273" subjects_affected="273" subjects_at_risk="500"/>
                <counts group_id="E2" events="299" subjects_affected="299" subjects_at_risk="597"/>
                <counts group_id="E3" events="299" subjects_affected="299" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="90" subjects_affected="90" subjects_at_risk="500"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="597"/>
                <counts group_id="E3" events="114" subjects_affected="114" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="92" subjects_affected="92" subjects_at_risk="500"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="597"/>
                <counts group_id="E3" events="120" subjects_affected="120" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="71" subjects_affected="71" subjects_at_risk="500"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="597"/>
                <counts group_id="E3" events="92" subjects_affected="92" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="135" subjects_affected="135" subjects_at_risk="500"/>
                <counts group_id="E2" events="109" subjects_affected="109" subjects_at_risk="597"/>
                <counts group_id="E3" events="152" subjects_affected="152" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="219" subjects_affected="219" subjects_at_risk="500"/>
                <counts group_id="E2" events="197" subjects_affected="197" subjects_at_risk="597"/>
                <counts group_id="E3" events="199" subjects_affected="199" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="132" subjects_affected="132" subjects_at_risk="500"/>
                <counts group_id="E2" events="105" subjects_affected="105" subjects_at_risk="597"/>
                <counts group_id="E3" events="136" subjects_affected="136" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="597"/>
                <counts group_id="E3" events="30" subjects_affected="30" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="500"/>
                <counts group_id="E2" events="87" subjects_affected="87" subjects_at_risk="597"/>
                <counts group_id="E3" events="52" subjects_affected="52" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

